Evaxion A/S (EVAX)
NASDAQ: EVAX · Real-Time Price · USD
2.440
-0.145 (-5.61%)
At close: Jun 27, 2025, 4:00 PM
2.450
+0.010 (0.41%)
After-hours: Jun 27, 2025, 4:00 PM EDT
Evaxion Revenue
Evaxion had revenue of $3.29M in the twelve months ending March 31, 2025, up 2,555.65% year-over-year. In the year 2024, Evaxion had annual revenue of $3.34M with 4,480.82% growth.
Revenue (ttm)
$3.29M
Revenue Growth
+2,555.65%
P/S Ratio
1.46
Revenue / Employee
$71,587
Employees
46
Market Cap
15.41M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
EVAX News
- 2 days ago - Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus - GlobeNewsWire
- 24 days ago - Evaxion receives grant funding to design new polio vaccine - GlobeNewsWire
- 4 weeks ago - Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call Transcript - Seeking Alpha
- 4 weeks ago - Evaxion announces business update and first quarter 2025 financial results - GlobeNewsWire
- 4 weeks ago - Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025 - Seeking Alpha
- 5 weeks ago - Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025 - GlobeNewsWire
- 5 weeks ago - Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01 - GlobeNewsWire
- 2 months ago - 80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting - GlobeNewsWire